Neil Exter

Partner, Third Rock Ventures

At Third Rock, Neil focuses on the formation, development and strategy of new companies. He has more than 30 years of operating, business development and strategy experience across the spectrum of emerging and established biotechnology and technology companies.


Neil holds an MBA as a Baker Scholar from Harvard Business School, an M.S. from Stanford University and a B.S. from Cornell University.

Neil Exter joined Third Rock Ventures in 2007 and has served in key leadership roles in the firm’s portfolio companies. Currently, he is interim chief business officer of Cedilla Therapeutics and board member and interim chief operating officer of Goldfinch Bio. He is currently on the board of directors of Cibiem, CytomX Therapeutics, Element Science, Pliant Therapeutics, Rhythm Pharmaceuticals and Motus Therapeutics, and is a board observer of Ambys Medicines. Formerly, he was interim chief business officer of REVOLUTION Medicines, Foundation Medicine and bluebird bio, as well as former interim chief operating officer of Constellation Pharmaceuticals.

Prior to joining Third Rock, Neil was chief business officer of Alantos Pharmaceuticals, leading the sale of the company to Amgen, and earlier, served as vice president for Millennium Pharmaceuticals, directing in-licensing and M&A. Earlier in his career, Neil held various executive and senior management roles within the high technology industry, including tenures at Hewlett Packard and Wang Laboratories.

He is a member of the Research Committee of Children’s Hospital Boston, a member of the investment committee of the Innovation Research Fund at Partners Healthcare and is a member of the board of directors of the New England Venture Capital Association.

Back to Who We Are